Cutler NR

General

Full name :

First name :

Mail :

Zip Code :

City :

Country :

Email :

Phone :

Fax :

Website :

Directory :

References (22)

Title : Galantamine hydrobromide: an agent for Alzheimer's disease - Zarotsky_2003_Am.J.Health.Syst.Pharm_60_446
Author(s) : Zarotsky V , Sramek JJ , Cutler NR
Ref : Am J Health Syst Pharm , 60 :446 , 2003
Abstract : Zarotsky_2003_Am.J.Health.Syst.Pharm_60_446
ESTHER : Zarotsky_2003_Am.J.Health.Syst.Pharm_60_446
PubMedSearch : Zarotsky_2003_Am.J.Health.Syst.Pharm_60_446
PubMedID: 12635450

Title : Estimation of the absolute bioavailability of rivastigmine in patients with mild to moderate dementia of the Alzheimer's type - Hossain_2002_Clin.Pharmacokinet_41_225
Author(s) : Hossain M , Jhee SS , Shiovitz T , McDonald C , Sedek G , Pommier F , Cutler NR
Ref : Clinical Pharmacokinetics , 41 :225 , 2002
Abstract : Hossain_2002_Clin.Pharmacokinet_41_225
ESTHER : Hossain_2002_Clin.Pharmacokinet_41_225
PubMedSearch : Hossain_2002_Clin.Pharmacokinet_41_225
PubMedID: 11929322

Title : Inhibition of acetyl- and butyryl-cholinesterase in the cerebrospinal fluid of patients with Alzheimer's disease by rivastigmine: correlation with cognitive benefit - Giacobini_2002_J.Neural.Transm.(Vienna)_109_1053
Author(s) : Giacobini E , Spiegel R , Enz A , Veroff AE , Cutler NR
Ref : J Neural Transm (Vienna) , 109 :1053 , 2002
Abstract : Giacobini_2002_J.Neural.Transm.(Vienna)_109_1053
ESTHER : Giacobini_2002_J.Neural.Transm.(Vienna)_109_1053
PubMedSearch : Giacobini_2002_J.Neural.Transm.(Vienna)_109_1053
PubMedID: 12111443

Title : The status of ongoing trials for mild cognitive impairment - Sramek_2001_Expert.Opin.Investig.Drugs_10_741
Author(s) : Sramek JJ , Veroff AE , Cutler NR
Ref : Expert Opin Investig Drugs , 10 :741 , 2001
Abstract : Sramek_2001_Expert.Opin.Investig.Drugs_10_741
ESTHER : Sramek_2001_Expert.Opin.Investig.Drugs_10_741
PubMedSearch : Sramek_2001_Expert.Opin.Investig.Drugs_10_741
PubMedID: 11281823

Title : Pharmacokinetic-pharmacodynamic modeling of rivastigmine, a cholinesterase inhibitor, in patients with Alzheimer's disease - Gobburu_2001_J.Clin.Pharmacol_41_1082
Author(s) : Gobburu JV , Tammara V , Lesko L , Jhee SS , Sramek JJ , Cutler NR , Yuan R
Ref : Journal of Clinical Pharmacology , 41 :1082 , 2001
Abstract : Gobburu_2001_J.Clin.Pharmacol_41_1082
ESTHER : Gobburu_2001_J.Clin.Pharmacol_41_1082
PubMedSearch : Gobburu_2001_J.Clin.Pharmacol_41_1082
PubMedID: 11583476

Title : Review of the next generation of Alzheimer's disease therapeutics: challenges for drug development - Cutler_2001_Prog.Neuropsychopharmacol.Biol.Psychiatry_25_27
Author(s) : Cutler NR , Sramek JJ
Ref : Prog Neuropsychopharmacol Biological Psychiatry , 25 :27 , 2001
Abstract : Cutler_2001_Prog.Neuropsychopharmacol.Biol.Psychiatry_25_27
ESTHER : Cutler_2001_Prog.Neuropsychopharmacol.Biol.Psychiatry_25_27
PubMedSearch : Cutler_2001_Prog.Neuropsychopharmacol.Biol.Psychiatry_25_27
PubMedID: 11263756

Title : Review of the acetylcholinesterase inhibitor galanthamine - Sramek_2000_Expert.Opin.Investig.Drugs_9_2393
Author(s) : Sramek JJ , Frackiewicz EJ , Cutler NR
Ref : Expert Opin Investig Drugs , 9 :2393 , 2000
Abstract : Sramek_2000_Expert.Opin.Investig.Drugs_9_2393
ESTHER : Sramek_2000_Expert.Opin.Investig.Drugs_9_2393
PubMedSearch : Sramek_2000_Expert.Opin.Investig.Drugs_9_2393
PubMedID: 11060814

Title : RBC cholinesterase inhibition: a useful surrogate marker for cholinesterase inhibitor activity in Alzheimer disease therapy? - Sramek_2000_Alzheimer.Dis.Assoc.Disord_14_216
Author(s) : Sramek JJ , Cutler NR
Ref : Alzheimer Disease & Associated Disorders , 14 :216 , 2000
Abstract : Sramek_2000_Alzheimer.Dis.Assoc.Disord_14_216
ESTHER : Sramek_2000_Alzheimer.Dis.Assoc.Disord_14_216
PubMedSearch : Sramek_2000_Alzheimer.Dis.Assoc.Disord_14_216
PubMedID: 11186600

Title : NXX-066 in patients with Alzheimer's disease: a bridging study - Sramek_1999_Life.Sci_64_1215
Author(s) : Sramek JJ , Hourani J , Jhee SS , Cutler NR
Ref : Life Sciences , 64 :1215 , 1999
Abstract : Sramek_1999_Life.Sci_64_1215
ESTHER : Sramek_1999_Life.Sci_64_1215
PubMedSearch : Sramek_1999_Life.Sci_64_1215
PubMedID: 10210264

Title : Cholinesterase inhibitors: a therapeutic strategy for Alzheimer disease - Krall_1999_Ann.Pharmacother_33_441
Author(s) : Krall WJ , Sramek JJ , Cutler NR
Ref : Annals of Pharmacotherapy , 33 :441 , 1999
Abstract : Krall_1999_Ann.Pharmacother_33_441
ESTHER : Krall_1999_Ann.Pharmacother_33_441
PubMedSearch : Krall_1999_Ann.Pharmacother_33_441
PubMedID: 10332536

Title : Safety and tolerability of metrifonate in patients with Alzheimer's disease: results of a maximum tolerated dose study - Cutler_1998_Life.Sci_62_1433
Author(s) : Cutler NR , Jhee SS , Cyrus P , Bieber F , TanPiengco P , Sramek JJ , Gulanski B
Ref : Life Sciences , 62 :1433 , 1998
Abstract : Cutler_1998_Life.Sci_62_1433
ESTHER : Cutler_1998_Life.Sci_62_1433
PubMedSearch : Cutler_1998_Life.Sci_62_1433
PubMedID: 9585171

Title : Dose-dependent CSF acetylcholinesterase inhibition by SDZ ENA 713 in Alzheimer's disease - Cutler_1998_Acta.Neurol.Scand_97_244
Author(s) : Cutler NR , Polinsky RJ , Sramek JJ , Enz A , Jhee SS , Mancione L , Hourani J , Zolnouni P
Ref : Acta Neurologica Scandinavica , 97 :244 , 1998
Abstract : Cutler_1998_Acta.Neurol.Scand_97_244
ESTHER : Cutler_1998_Acta.Neurol.Scand_97_244
PubMedSearch : Cutler_1998_Acta.Neurol.Scand_97_244
PubMedID: 9576639

Title : Effects of xanomeline, a selective muscarinic receptor agonist, on cognitive function and behavioral symptoms in Alzheimer disease - Bodick_1997_Arch.Neurol_54_465
Author(s) : Bodick NC , Offen WW , Levey AI , Cutler NR , Gauthier SG , Satlin A , Shannon HE , Tollefson GD , Rasmussen K , Bymaster FP , Hurley DJ , Potter WZ , Paul SM
Ref : Archives of Neurology , 54 :465 , 1997
Abstract : Bodick_1997_Arch.Neurol_54_465
ESTHER : Bodick_1997_Arch.Neurol_54_465
PubMedSearch : Bodick_1997_Arch.Neurol_54_465
PubMedID: 9109749

Title : Safety\/tolerability trial of SDZ ENA 713 in patients with probable Alzheimer's disease - Sramek_1996_Life.Sci_58_1201
Author(s) : Sramek JJ , Anand R , Wardle TS , Irwin P , Hartman RD , Cutler NR
Ref : Life Sciences , 58 :1201 , 1996
Abstract : Sramek_1996_Life.Sci_58_1201
ESTHER : Sramek_1996_Life.Sci_58_1201
PubMedSearch : Sramek_1996_Life.Sci_58_1201
PubMedID: 8614273

Title : Acetylcholinesterase inhibition by zifrosilone: pharmacokinetics and pharmacodynamics - Cutler_1995_Clin.Pharmacol.Ther_58_54
Author(s) : Cutler NR , Seifert RD , Schleman MM , Sramek JJ , Szylleyko OJ , Howard DR , Barchowsky A , Wardle TS , Brass EP
Ref : Clinical Pharmacology & Therapeutics , 58 :54 , 1995
Abstract : Cutler_1995_Clin.Pharmacol.Ther_58_54
ESTHER : Cutler_1995_Clin.Pharmacol.Ther_58_54
PubMedSearch : Cutler_1995_Clin.Pharmacol.Ther_58_54
PubMedID: 7628183

Title : A multiple-dose safety trial of eptastigmine in Alzheimer's disease, with pharmacodynamic observations of red blood cell cholinesterase - Sramek_1995_Life.Sci_56_319
Author(s) : Sramek JJ , Block GA , Reines SA , Sawin SF , Barchowsky A , Cutler NR
Ref : Life Sciences , 56 :319 , 1995
Abstract : Sramek_1995_Life.Sci_56_319
ESTHER : Sramek_1995_Life.Sci_56_319
PubMedSearch : Sramek_1995_Life.Sci_56_319
PubMedID: 7837931

Title : Scientific and ethical concerns in clinical trials in Alzheimer's patients: the bridging study [see comments] - Cutler_1995_Eur.J.Clin.Pharmacol_48_421
Author(s) : Cutler NR , Sramek JJ
Ref : European Journal of Clinical Pharmacology , 48 :421 , 1995
Abstract : Cutler_1995_Eur.J.Clin.Pharmacol_48_421
ESTHER : Cutler_1995_Eur.J.Clin.Pharmacol_48_421
PubMedSearch : Cutler_1995_Eur.J.Clin.Pharmacol_48_421
PubMedID: 8582458

Title : Tacrine in Alzheimer's disease -
Author(s) : Cutler NR , Sramek JJ
Ref : N Engl J Med , 328 :808\; author reply 809 , 1993
PubMedID: 8437603

Title : Alzheimer's patients should be included in phase I clinical trials to evaluate compounds for Alzheimer's disease - Cutler_1992_J.Geriatr.Psychiatry.Neurol_5_192
Author(s) : Cutler NR , Sramek JJ , Murphy MF , Nash RJ
Ref : J Geriatr Psychiatry Neurol , 5 :192 , 1992
Abstract : Cutler_1992_J.Geriatr.Psychiatry.Neurol_5_192
ESTHER : Cutler_1992_J.Geriatr.Psychiatry.Neurol_5_192
PubMedSearch : Cutler_1992_J.Geriatr.Psychiatry.Neurol_5_192
PubMedID: 1418362

Title : Implications of the study population in the early evaluation of anticholinesterase inhibitors for Alzheimer's disease - Cutler_1992_Ann.Pharmacother_26_1118
Author(s) : Cutler NR , Sramek JJ , Murphy MF , Nash RJ
Ref : Annals of Pharmacotherapy , 26 :1118 , 1992
Abstract : Cutler_1992_Ann.Pharmacother_26_1118
ESTHER : Cutler_1992_Ann.Pharmacother_26_1118
PubMedSearch : Cutler_1992_Ann.Pharmacother_26_1118
PubMedID: 1421679

Title : Clinical safety, tolerance, and plasma levels of the oral anticholinesterase 1,2,3,4-tetrahydro-9-aminoacridin-1-oL-maleate (HP 029) in Alzheimer's disease: preliminary findings - Cutler_1990_J.Clin.Pharmacol_30_556
Author(s) : Cutler NR , Murphy MF , Nash RJ , Prior PL , De Luna DM
Ref : Journal of Clinical Pharmacology , 30 :556 , 1990
Abstract : Cutler_1990_J.Clin.Pharmacol_30_556
ESTHER : Cutler_1990_J.Clin.Pharmacol_30_556
PubMedSearch : Cutler_1990_J.Clin.Pharmacol_30_556
PubMedID: 2355106

Title : Steady-state pharmacokinetics of tacrine in patients with Alzheimer's disease - Cutler_1990_Psychopharmacol.Bull_26_231
Author(s) : Cutler NR , Sedman AJ , Prior P , Underwood BA , Selen A , Balogh L , Kinkel AW , Gracon SI , Gamzu ER
Ref : Psychopharmacol Bull , 26 :231 , 1990
Abstract : Cutler_1990_Psychopharmacol.Bull_26_231
ESTHER : Cutler_1990_Psychopharmacol.Bull_26_231
PubMedSearch : Cutler_1990_Psychopharmacol.Bull_26_231
PubMedID: 2236461